“Optimization of potent and selective Ataxia Telangiectasia Mutated (ATM) inhibitors suitable for a proof-of-concept study in Huntington’s disease models”.

“Optimization of potent and selective Ataxia Telangiectasia Mutated (ATM) inhibitors suitable for a proof-of-concept study in Huntington’s disease models”.

Publication date: Mar 06, 2019

Genetic and pharmacological evidence indicates that reduction of ataxia telangiectasia-mutated (ATM) kinase activity can ameliorate mutant huntingtin (mHTT) toxicity in cellular and animal models of Huntington’s disease (HD), suggesting that selective inhibition of ATM could provide a novel clinical intervention to treat HD. Here we describe the development and characterization of ATM inhibitor molecules to enable in vivo proof-of-concept studies in HD animal models. Starting from previously reported ATM inhibitors, we aimed with few modifications to increase brain exposure by decreasing P-glycoprotein (P-gp) liability, while maintaining potency and selectivity. Here we report brain-penetrant ATM inhibitors that have robust pharmacodynamic (PD) effects consistent with ATM kinase inhibition in mouse brain and an understood pharmacokinetic/pharmacodynamic (PK/PD) relationship. Compound 17, engages ATM kinase and shows robust dose-dependent inhibition of X-ray irradiation-induced KAP1 phosphorylation in mouse brain. Furthermore, compound 17 protects against mHTT (Q73)-induced cytotoxicity in a cortical-striatal cell model of HD.

Toledo-Sherman, L.M., Breccia, P., Cachope, R., , Bate, , Angulo-Herrera, Wishart, G., Matthews, K.L., Martin, S.L., Cox, H.C., McAllister, G., Penrose, S.D., Vater, H., Esmieu, W., Van de Po”el, A., Van de Bospoort, R., Strijbosch, A., Lamers, M.B.A.C., Leonard, P.M., Jarvis, R., Blackaby, W., Barnes, K., Eznarriaga, M., Dowler, S., Smith, G.D., Fischer, D., Lazari, O., Yates, D., Rose, M., Jang, S.W., , Mu~noz-Sanjuan, and Dominguez, C. “Optimization of potent and selective Ataxia Telangiectasia Mutated (ATM) inhibitors suitable for a proof-of-concept study in Huntington’s disease models”. 06382. 2019 J Med Chem.

Concepts Keywords
Ataxia Telangiectasia ATM
ATM Branches of biology
Brain Ataxia–telangiectasia
Cortical ATM serine/threonine kinase
Cytotoxicity Proteins
Glycoprotein Organ systems
Huntingtin
Huntington
Inhibitor
Mutant
Penetrant
Pharmacodynamic
Pharmacokinetic
Pharmacological
Phosphorylation
Striatal
Toxicity
Vivo
X Ray

Semantics

Type Source Name
gene UNIPROT TRIM28
gene UNIPROT CDKN3
gene UNIPROT RAB35
gene UNIPROT SH3YL1
gene UNIPROT ABCB1
disease MESH development
gene UNIPROT ATM
disease DOID Ataxia Telangiectasia
disease MESH Ataxia Telangiectasia

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *